

**BRISTOL-MYERS SQUIBB COMPANY**  
**WORLDWIDE NET SALES FROM CONTINUING OPERATIONS BY PRODUCT**  
**QUARTERLY SALES TREND ANALYSIS**  
(\$ in millions)

	2007							2008							% Change		FX Impact	
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
<b>Continuing Operations</b>	\$4,063	\$4,471	\$8,534	\$4,601	\$13,135	\$5,058	\$18,193	\$4,891	\$5,203	\$10,094	\$5,254	\$15,348	\$5,249	\$20,597	4%	13%	-4%	2%
<b>PHARMACEUTICALS</b>	3,457	3,851	7,308	3,926	11,234	4,388	15,622	4,188	4,475	8,663	4,510	13,173	4,542	17,715	4%	13%	-4%	2%
<b>Cardiovascular</b>	1,475	1,763	3,238	1,793	5,031	1,938	6,969	1,824	1,927	3,751	1,943	5,694	1,937	7,631	-	9%	-	-
Plavix	938	1,189	2,127	1,254	3,381	1,374	4,755	1,308	1,387	2,695	1,439	4,134	1,469	5,603	7%	18%	-2%	1%
Avapro/ Avalide	270	297	567	309	876	328	1,204	305	335	640	334	974	316	1,290	-4%	7%	-6%	2%
Pravachol	135	132	267	86	353	90	443	73	69	142	34	176	27	203	-70%	-54%	-5%	2%
<b>Virology</b>	590	608	1,198	647	1,845	752	2,597	734	791	1,525	824	2,349	812	3,161	8%	22%	-	-
Reyataz	263	254	517	273	790	334	1,124	297	324	621	342	963	329	1,292	-1%	15%	-5%	2%
Sustiva Franchise <sup>(a)</sup>	226	233	459	237	696	260	956	273	282	555	294	849	300	1,149	15%	20%	-4%	2%
Baraclude	45	59	104	72	176	99	275	108	136	244	144	388	153	541	55%	97%	-5%	6%
<b>Oncology</b>	355	360	715	402	1,117	445	1,562	436	474	910	447	1,357	462	1,819	4%	16%	-	-
Eributux	160	162	322	185	507	185	692	187	196	383	184	567	182	749	-2%	8%	-	-
Taxol	111	95	206	102	308	114	422	94	101	195	91	286	99	385	-13%	-9%	5%	8%
Sprycel	21	35	56	46	102	56	158	66	76	142	82	224	86	310	54%	96%	-13%	5%
Ixempra	-	-	-	-	-	15	15	25	26	51	25	76	25	101	67%	*	-	*
<b>Affective (Psychiatric) Disorders</b>	408	458	866	467	1,333	511	1,844	498	575	1,073	607	1,680	641	2,321	25%	26%	-	-
Abilify <sup>(b)</sup>	366	412	778	420	1,198	462	1,660	454	529	983	564	1,547	606	2,153	31%	30%	-3%	1%
<b>Immunoscience</b>	41	55	96	60	156	75	231	87	106	193	119	312	129	441	72%	91%	-	-
Orencia	41	55	96	60	156	75	231	87	106	193	119	312	129	441	72%	91%	-4%	1%
<b>NUTRITIONALS</b>	606	620	1,226	675	1,901	670	2,571	703	728	1,431	744	2,175	707	2,882	6%	12%	-5%	2%
Enfamil	254	267	521	281	802	280	1,082	290	287	577	295	872	285	1,157	2%	7%	-3%	1%

\* In excess of +/- 200%

(a) The Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla.

(b) Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.